Saliva biomarker review identifies common candidates, with clinical validation still needed
Cortisol and interleukins were the most frequently used markers in studies of cancer and infections, but the abstract does not show how accurately they predict outcomes.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
The review identified cortisol and interleukins as the salivary markers most often used to study prognosis in cancer and infectious diseases. That finding describes research use, not demonstrated predictive accuracy. The authors call for standardization and clinical validation before routine use, and the abstract does not report whether testing improves patient outcomes.
This brief is based on the abstract. It provides no disease-specific results, predictive performance estimates or findings from its risk-of-bias assessment, so the reliability of any particular prognostic test cannot be judged.
What the review asked
Researchers searched for clinical trials that used saliva biomarkers to assess prognosis, meaning the expected course of disease. They summarized the eligible reports qualitatively, focusing on which markers were being used.
What clinical potential means here
The conclusion describes potential for non-invasive monitoring and prognostic assessment. It does not identify a validated test, a decision threshold or a clinical setting in which using a saliva marker changes care successfully.
The original publication
Salivary biomarkers for the prognosis of oncological and infectious diseases: a systematic review.
Arbildo-Vega HI, Panda S, Cruzado-Oliva FH et al.
Front Dent Med · 2025
- PubMed ID
- 41089877
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.